Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice - Neuropathies et Innovations Thérapeutiques Accéder directement au contenu
Article Dans Une Revue Frontiers in Pharmacology Année : 2021

Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice

Résumé

Oxaliplatin is a key drug for colorectal cancer that causes OXP-induced peripheral neuropathy, a dose-limiting effect characterized by cold and tactile hyperesthesia. The relationship between the sensory nervous system and modulation of the renin-angiotensin system has been described, focusing on pain and neurodegeneration in several animal models. We assessed the effect of the RAS modulator, ramipril, an angiotensin converting-enzyme inhibitor in a mouse model of OXP-induced acute pain syndrome. OXP was administered in Swiss mice at a cumulative dose of 15 mg/kg (3 x 5 mg/kg/3 days, i.p.). RAM was administered i.p. every day from 24 h before the first OXP injection until the end of the experiments. We evaluated OIAS development and treatment effects by sensorimotor tests, intraepidermal nerve fiber and dorsal root ganglia-neuron immunohistochemical analyses, and sciatic nerve ultrastructural analysis. OXP-treated mice showed tactile allodynia and cold hypersensitivity, without motor impairment and evidence of nerve degeneration. RAM prevented cold sensitivity and improved recovery of normal tactile sensitivity in OXP-treated mice. Our finding that RAM alleviates OXP-induced pain is a step towards evaluating its therapeutic potential in patients receiving OXP treatment.

Dates et versions

hal-03402611 , version 1 (25-10-2021)

Identifiants

Citer

Hichem Bouchenaki, Aurore Danigo, Amandine Bernard, Flavien Bessaguet, Laurence Richard, et al.. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Frontiers in Pharmacology, 2021, 12, ⟨10.3389/fphar.2021.712442⟩. ⟨hal-03402611⟩
41 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More